126 related articles for article (PubMed ID: 38902152)
1. Dalbavancin as sequential therapy in infective endocarditis: Real-life experience in elder and comorbid patients.
Aparicio-Minguijón E; Boán J; Terrón A; Heredia C; Puente C; Pérez-Jacoiste Asín A; Orellana MÁ; Domínguez L; Caro JM; López-Gude MJ; Aguilar-Blanco EM; Eixerés-Esteve A; López-Medrano F
Enferm Infecc Microbiol Clin (Engl Ed); 2024 Jun; ():. PubMed ID: 38902152
[TBL] [Abstract][Full Text] [Related]
2. Dalbavancin as consolidation therapy for infective endocarditis in patients with comorbidity. A real world experience.
Brandariz-Núñez D; Luances-Rodríguez A; Feijoo-Vilanova P; Gutiérrez-Urbón JM; Ramudo-Cela L; Martín-Herranz MI; Margusino-Framiñán L
Rev Esp Quimioter; 2024 Aug; 37(4):334-340. PubMed ID: 38881525
[TBL] [Abstract][Full Text] [Related]
3. Comparison of dalbavancin with standard of care in the management of infective endocarditis: efficacy, safety, and cost analysis.
Suárez M; Pérez-Landeiro A; Sanjurjo A; Lima O; Sousa A; López A; Martínez-Lamas L; Cabrera X; Rubianes M; Pérez-Rodríguez MT
Int J Infect Dis; 2024 Jan; 138():41-45. PubMed ID: 37931892
[TBL] [Abstract][Full Text] [Related]
4. EN-DALBACEN 2.0 Cohort: real-life study of dalbavancin as sequential/consolidation therapy in patients with infective endocarditis due to Gram-positive cocci.
Hidalgo-Tenorio C; Sadyrbaeva-Dolgova S; Enríquez-Gómez A; Muñoz P; Plata-Ciezar A; Miró JM; Alarcón A; Martínez-Marcos FJ; Loeches B; Escrihuela-Vidal F; Vinuesa D; Herrero C; Boix-Palop L; Del Mar Arenas M; Vázquez EG; de Las Revillas FA; Pasquau J;
Int J Antimicrob Agents; 2023 Sep; 62(3):106918. PubMed ID: 37442488
[TBL] [Abstract][Full Text] [Related]
5. Dalbavancin as consolidation antibiotic treatment in infective endocarditis, cardiac implantable electronic devices infection and bacteremia: Clinical experience of 7 years.
Salinas-Botrán A; Olmos-Blanco C; Fernández de Velasco-Pérez D; Guzmán-Carreras A; Morales-Rosas A; Gómez-Ramírez D
Enferm Infecc Microbiol Clin (Engl Ed); 2024 May; ():. PubMed ID: 38763866
[TBL] [Abstract][Full Text] [Related]
6. DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci.
Hidalgo-Tenorio C; Vinuesa D; Plata A; Martin Dávila P; Iftimie S; Sequera S; Loeches B; Lopez-Cortés LE; Fariñas MC; Fernández-Roldan C; Javier-Martinez R; Muñoz P; Arenas-Miras MDM; Martínez-Marcos FJ; Miró JM; Herrero C; Bereciartua E; De Jesus SE; Pasquau J
Ann Clin Microbiol Antimicrob; 2019 Oct; 18(1):30. PubMed ID: 31629409
[TBL] [Abstract][Full Text] [Related]
7. Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections.
Veve MP; Patel N; Smith ZA; Yeager SD; Wright LR; Shorman MA
Int J Antimicrob Agents; 2020 Dec; 56(6):106210. PubMed ID: 33223119
[TBL] [Abstract][Full Text] [Related]
8. Outpatient parenteral antimicrobial therapy in Enterococcus faecalis infective endocarditis.
Gil-Navarro MV; Lopez-Cortes LE; Luque-Marquez R; Galvez-Acebal J; de Alarcon-Gonzalez A
J Clin Pharm Ther; 2018 Apr; 43(2):220-223. PubMed ID: 29030859
[TBL] [Abstract][Full Text] [Related]
9. Infective endocarditis after transcatheter aortic valve implantation: Contributions of a single-centre experience on incidence and associated factors.
Rodríguez-Vidigal FF; Nogales-Asensio JM; Calvo-Cano A; González-Fernández R; Martínez-Carapeto A; Gómez-Sanchez I; Bengla-Limpo B; Merchán-Herrera A; Nogales-Muñoz N; Vera-Tomé A; Muñoz-Sanz A; López-Mínguez JR
Enferm Infecc Microbiol Clin (Engl Ed); 2019; 37(7):428-434. PubMed ID: 30389267
[TBL] [Abstract][Full Text] [Related]
10. Dalbavancin for infective endocarditis: a single centre experience.
Durante-Mangoni E; Boccia F; Ursi MP; Karruli A; Andini R; Galdo M; Zampino R
J Chemother; 2021 Jul; 33(4):256-262. PubMed ID: 33073724
[TBL] [Abstract][Full Text] [Related]
11. A Dalbavancin for Successful Treatment of Infective Endocarditis Caused by
Teigell-Muñoz FJ; Mateos-González M; Bernal Hertfelder E; Sánchez de Torre A; García-Ferrón M; de Cáceres Velasco C; Bueno Muiño C
Eur J Case Rep Intern Med; 2023; 10(1):003654. PubMed ID: 36819647
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial activity of dalbavancin tested against Gram-positive organisms isolated from patients with infective endocarditis in US and European medical centres.
Sader HS; Mendes RE; Pfaller MA; Flamm RK
J Antimicrob Chemother; 2019 May; 74(5):1306-1310. PubMed ID: 30753485
[TBL] [Abstract][Full Text] [Related]
13. Use of dalbavancin in infective endocarditis: a case series.
Guleri A; More R; Sharma R; Wong M; Abdelrahman A
JAC Antimicrob Resist; 2021 Sep; 3(3):dlab099. PubMed ID: 34396119
[TBL] [Abstract][Full Text] [Related]
14. Dalbavancin Sequential Therapy for Gram-Positive Bloodstream Infection: A Multicenter Observational Study.
Rebold N; Alosaimy S; Pearson JC; Dionne B; Taqi A; Lagnf A; Lucas K; Biagi M; Lombardo N; Eudy J; Anderson DT; Mahoney MV; Kufel WD; D'Antonio JA; Jones BM; Frens JJ; Baumeister T; Geriak M; Sakoulas G; Farmakiotis D; Delaportas D; Larew J; Veve MP; Rybak MJ
Infect Dis Ther; 2024 Mar; 13(3):565-579. PubMed ID: 38427289
[TBL] [Abstract][Full Text] [Related]
15. Real-World Data Regarding Dalbavancin Use before and during the COVID-19 Pandemic-A Single-Center Retrospective Study.
Ioannou P; Wolff N; Mathioudaki A; Spanias C; Spernovasilis N; Kofteridis DP
Antibiotics (Basel); 2023 Jul; 12(7):. PubMed ID: 37508301
[TBL] [Abstract][Full Text] [Related]
16. Teicoplanin for treating enterococcal infective endocarditis: A retrospective observational study from a referral centre in Spain.
Escolà-Vergé L; Fernández-Hidalgo N; Rodríguez-Pardo D; Pigrau C; González-López JJ; Bartolomé R; Almirante B
Int J Antimicrob Agents; 2019 Feb; 53(2):165-170. PubMed ID: 30315920
[TBL] [Abstract][Full Text] [Related]
17. Dalbavancin Efficacy and Impact on Hospital Length-of-Stay and Treatment Costs in Different Gram-Positive Bacterial Infections.
Poliseno M; Bavaro DF; Brindicci G; Luzzi G; Carretta DM; Spinarelli A; Messina R; Miolla MP; Achille TI; Dibartolomeo MR; Dell'Aera M; Saracino A; Angarano G; Favale S; D'Agostino C; Moretti B; Signorelli F; Taglietti C; Carbonara S
Clin Drug Investig; 2021 May; 41(5):437-448. PubMed ID: 33884583
[TBL] [Abstract][Full Text] [Related]
18. Dalbavancin as sequential therapy for infective endocarditis due to Gram-positive organisms: a review.
Fazili T; Bansal E; Garner D; Gomez M; Stornelli N
Int J Antimicrob Agents; 2023 Apr; 61(4):106749. PubMed ID: 36758775
[TBL] [Abstract][Full Text] [Related]
19. The changing landscape of infective endocarditis in South Africa.
De Villiers MC; Viljoen CA; Manning K; Van der Westhuizen C; Seedat A; Rath M; Graham M; Ntsekhe M
S Afr Med J; 2019 Jul; 109(8):592-596. PubMed ID: 31456555
[TBL] [Abstract][Full Text] [Related]
20. Dalbavancin for treating prosthetic joint infections caused by Gram-positive bacteria: A proposal for a low dose strategy. A retrospective cohort study.
Buzón Martín L; Mora Fernández M; Perales Ruiz JM; Ortega Lafont M; Álvarez Paredes L; Morán Rodríguez MA; Fernández Regueras M; Machín Morón MA; Mejías Lobón G
Rev Esp Quimioter; 2019 Dec; 32(6):532-538. PubMed ID: 31642637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
